FacebookTwitterGoogle+RedditEmail

Merck is a Repeat Offender

Even as Merck seeks closure on its Vioxx nightmare by paying $4.85 billion to tens of thousands of plaintiffs who took the painkiller–not that it did anything wrong–the bad ink continues.

Articles about Vioxx, withdrawn from the market in 2004 for doubling stroke and heart attack risk, in the April 16, 2008 JAMA charge Merck disguised mortality data it submitted from Vioxx trials to the FDA and wrote the scientific papers itself it claimed were penned by doctors.

Merck transposed its own clinical study results of 34 deaths in the Vioxx group and 12 in the placebo group to 29 deaths in the Vioxx group and 17 in the placebo group when it submitted data to the FDA write Bruce Psaty, MD, PhD; and Richard Kronmal, PhD, professors at the University of Washington in JAMA. Worse, Merck knew as early as 2001 that participants in Vioxx trials who had Alzheimer’s disease were dying at three times the rate of those taking placebo.

Articles extolling Vioxx as the Super Aspirin were also a product of Merck machinations says another article in JAMA. They were actually ghostwritten from Merck’s own research with doctors’ “guest author” names attached as an afterthought write Joseph S. Ross, MD, MHS, Kevin P. Hill, MD, MHS and two other authors on the basis of 250 court documents they examined.

Merck marketing, with Schering-Plough, of Vytorin, the cholesterol drug exposed as no more effective than generics in January, is also under scrutiny in a House Energy and Commerce Committee investigation.

In fact it was the investigation, begun in December 2007, that pried loose the results of the Enhance study which Merck and Schering-Plough were sitting on since April 2006– despite clearance by consultant Michiel Bots–while they tried to change end points apparently to spin the data and unloaded Schering-Plough stock, say published reports.

“I would like for the companies to explain why they didn’t proceed with data analysis after Dr. Bots’ independent consultation report indicated the data were ‘fine,'” Rep. John Dingell (D-Mich.), chairman of the committee, said to The Star-Ledger.

In May, a House Energy and Commerce subcommittee hearing into deceptive drug industry marketing also looked at Merck’s multimillion dollar “cholesterol from two sources: food and family” Vytorin campaign in light of the suppressed Enhance study results.

“Many consumers may not have taken Vytorin had they been aware of the study results,” said Rep. Bart Stupak (D-Mich.) to Deepak Khanna, senior vice president of the Merck and Schering-Plough joint venture, according to The Star-Ledger.

Nor are other Merck drugs doing well.

Fosamax, Merck’s osteoporosis drug, was already facing more than 100 suits for causing osteonecrosis of the jaw or jaw bone death–added to its warning label in 2005–when a new wrinkle emerged. Women who took Fosamax were twice as likely to have atrial fibrillation, a chronically irregular heartbeat, as those who didn’t says an article in the April 28, 2008 Archives of Internal Medicine, echoing a New England Journal of Medicine article last year.

And Singulair, Merck’s allergy and asthma pill is under FDA review for possible suicide side effects.

But even as jokes appear about the number of Merck staffers required to change a light bulb–10 to call it a breakthrough, 10 to conference call Wall Street, 10 to suppress evidence it’s been done before and more safely and one to change the bulb–Merck is repeating its mistakes.

In April, it tried to launch a new cholesterol drug, Cordaptive, that combines niacin, a B vitamin which raises HDL but causes facial flushing with laropiprant, an anti-flushing drug, without waiting for study results, like it did with Vytorin.

Not only did the company want to start making money before safety was established in a 20,000 patient study that ends in 2012, Merck admits there are “theoretical” safety concerns about laropiprant’s effect on the liver, according to The Star-Ledger.

Plus, the science behind Cordaptive–that raising HDL, or good cholesterol will result in fewer heart attacks and strokes–is no longer reliable, says The Star-Ledger’s George E. Jordan.

“The utility of biomarkers was turned on its ear in a study of GlaxoSmithKlein’s diabetes pill Avandia, which found it lowered blood sugar in patients but resulted in elevated heart risks,” he writes. “Vytorin dramatically reduced LDL, but it worked no better at clearing clogged arteries than a generic drug five times less expensive.”

No wonder the FDA rejected Cordaptive out of hand, causing Merck to cut 1,200 sales jobs and add to its anti-fan club.

Merck didn’t even do simple market research. Vitamin and drug stores have been selling flush free niacin for years. A bottle costs about $9.95.

MARTHA ROSENBERG is staff cartoonist on the Evanston Roundtable. She can be reached at mrosenberg@evmark.org

Your Ad Here

 

 

 

 

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

December 17, 2018
Susan Abulhawa
Marc Lamont Hill’s Detractors are the True Anti-Semites
Jake Palmer
Viktor Orban, Trump and the Populist Battle Over Public Space
Martha Rosenberg
Big Pharma Fights Proposal to Keep It From Looting Medicare
David Rosen
December 17th: International Day to End Violence against Sex Workers
Binoy Kampmark
The Case that Dare Not Speak Its Name: the Conviction of Cardinal Pell
Dave Lindorff
Making Trump and Other Climate Criminals Pay
Bill Martin
Seeing Yellow
Julian Vigo
The World Google Controls and Surveillance Capitalism
ANIS SHIVANI
What is Neoliberalism?
James Haught
Evangelicals Vote, “Nones” Falter
Vacy Vlanza
The Australian Prime Minister’s Rapture for Jerusalem
Martin Billheimer
Late Year’s Hits for the Hanging Sock
Weekend Edition
December 14, 2018
Friday - Sunday
Andrew Levine
A Tale of Two Cities
Peter Linebaugh
The Significance of The Common Wind
Bruce E. Levine
The Ketamine Chorus: NYT Trumpets New Anti-Suicide Drug
Jeffrey St. Clair
Roaming Charges: Fathers and Sons, Bushes and Bin Ladens
Kathy Deacon
Coffee, Social Stratification and the Retail Sector in a Small Maritime Village
Nick Pemberton
Praise For America’s Second Leading Intellectual
Robert Hunziker
The Yellow Vest Insurgency – What’s Next?
Patrick Cockburn
The Yemeni Dead: Six Times Higher Than Previously Reported
Nick Alexandrov
George H. W. Bush: Another Eulogy
Brian Cloughley
Principles and Morality Versus Cash and Profit? No Contest
Michael F. Duggan
Climate Change and the Limits of Reason
Victor Grossman
Sighs of Relief in Germany
Ron Jacobs
A Propagandist of Privatization
Robert Fantina
What Does Beto Have Against the Palestinians?
Richard Falk – Daniel Falcone
Sartre, Said, Chomsky and the Meaning of the Public Intellectual
Andrew Glikson
Crimes Against the Earth
Robert Fisk
The Parasitic Relationship Between Power and the American Media
Stephen Cooper
When Will Journalism Grapple With the Ethics of Interviewing Mentally Ill Arrestees?
Jill Richardson
A War on Science, Morals and Law
Ron Jacobs
A Propagandist of Privatization
Evaggelos Vallianatos
It’s Not Easy Being Greek
Nomi Prins 
The Inequality Gap on a Planet Growing More Extreme
John W. Whitehead
Know Your Rights or You Will Lose Them
David Swanson
The Abolition of War Requires New Thoughts, Words, and Actions
J.P. Linstroth
Primates Are Us
Bill Willers
The War Against Cash
Jonah Raskin
Doris Lessing: What’s There to Celebrate?
Ralph Nader
Are the New Congressional Progressives Real? Use These Yardsticks to Find Out
Binoy Kampmark
William Blum: Anti-Imperial Advocate
Medea Benjamin – Alice Slater
Green New Deal Advocates Should Address Militarism
John Feffer
Review: Season 2 of Trump Presidency
Rich Whitney
General Motors’ Factories Should Not Be Closed. They Should Be Turned Over to the Workers
Christopher Brauchli
Deported for Christmas
FacebookTwitterGoogle+RedditEmail